Table 2.
MR estimates examining the association of genetically proxied perturbation of PPARG with site-specific and overall cancer risk
| Outcome | N (cases; controls) | OR (95% CI) | p value |
|---|---|---|---|
| Breast cancer | 122,977; 105,974 | 0.67 (0.43, 1.04) | 0.08 |
| ER+ breast cancer | 69,501; 105,974 | 0.57 (0.38, 0.85) | 6.45×10−3 |
| ER− breast cancer | 21,468; 105,974 | 1.14 (0.64, 2.01) | 0.66 |
| Colorectal cancer | 58,221; 67,694 | 0.95 (0.51, 1.75) | 0.86 |
| Colon cancer | 32,002; 64,159 | 1.22 (0.72, 2.08) | 0.46 |
| Rectal cancer | 16,212; 64,159 | 0.82 (0.25, 2.71) | 0.75 |
| Prostate cancer | 79,148; 61,106 | 1.75 (1.07, 2.85) | 0.02 |
| Advanced prostate cancera | 15,167; 58,308 | 1.64 (0.62, 4.33) | 0.32 |
| Overall cancer risk | 27,483; 372,016 | 0.72 (0.44, 1.19) | 0.20 |
ORs (95% CIs) are scaled to represent the effect of genetically proxied perturbation of PPARG equivalent to a 1 unit lowering of IRNT HbA1c (mmol/mol)
aAdvanced prostate cancer is defined as metastatic disease, Gleason score ≥8, prostate-specific antigen >100 or prostate cancer-related death